Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors

Download All
In this online program based on a series of CLL Webinars, experts discuss evidence-based best practices in using BTK inhibitors to treat patients with CLL. Watch the on-demand Webcast and download the slides now.
Danielle Brander, MD
Jeff P. Sharman, MD

ClinicalThought

Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.

Danielle Brander, MD Released: September 22, 2020

The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.

Danielle Brander, MD Released: September 29, 2020

Get the latest information on how investigational noncovalent BTK inhibitors, such as LOXO-305 and ARQ 531, may help treat patients with CLL and resistance to currently available BTK inhibitors.

Jeff P. Sharman, MD Released: September 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings